Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound
Berobenatide is one of the keys to Pfizer's future.
Overview
The past few years have been rough on Pfizer (NYSE: PFE). The company has generally posted subpar financial results due to weakness within its coronavirus franchise, which once helped it become the first biopharmaceutical company to achieve $100 billion in annual sales. The drugmaker is looking to turn things around by developing potential blockbuster products, and one of its most promising candidates is berobenatide, an investigational weight loss therapy. The anti-obesity market is growing rapidly and could be worth $190 billion by 2035, compared to just $79 billion last year, according to some estimates. Could Pfizer's berobenatide help the company capitalize on this large opportunity?
Image source: The Motley Fool.
Pfizer will have to compete against the leaders in the weight-loss market, Eli Lilly, whose Zepbound is the best-selling drug in this niche, and Novo Nordisk, a pioneer in the market and the company behind Wegovy, perhaps the best-known brand in the field. How does berobenatide compare to Wegovy and Zepbound? It's hard to say without head-to-head clinical trials, but the data we do have so far suggest that Pfizer's candidate could be highly competitive.
Details
Source
Originally published at www.fool.com.